Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis

BACKGROUND: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-γ1b (rIFN-γb) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. METHODOLOGY/PRINCIPA...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawson, Rod, Condos, Rany, Tse, Doris, Huie, Maryann L., Ress, Stanley, Tseng, Chi-Hong, Brauns, Clint, Weiden, Michael, Hoshino, Yoshihiko, Bateman, Eric, Rom, William N.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737621/
https://www.ncbi.nlm.nih.gov/pubmed/19753300
http://dx.doi.org/10.1371/journal.pone.0006984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737621/
https://www.ncbi.nlm.nih.gov/pubmed/19753300
http://dx.doi.org/10.1371/journal.pone.0006984

Ejemplares similares